Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células

ResumoIntroduçãoEm 2006, a Unidade de Pneumologia Oncológica do Serviço de Pneumologia do Centro Hospitalar de Vila Nova de Gaia/Espinho iniciou a sequenciação da mutação do recetor do fator de crescimento epidérmico (EGFR) em doentes com CPNPC selecionados e desde 2010 realiza a sequenciação sistematicamente em todos os doentes, independentemente da histologia, hábitos tabágicos, idade ou sexo. O objetivo deste trabalho foi caracterizar o grupo de doentes que efetuou a sequenciação entre 2006-2010, determinar a frequência da mutação EGFR, avaliar as sobrevidas globais e após uso de inibidores da tirosina quinase (ITK), nos doentes que efetuaram esta terapêutica em 2.a e 3.a linha com conhecimento do estado da mutação do EGFR.MétodosAnálise estatística descritiva dos doentes que efetuaram sequenciação EGFR em 2006-2010 e sobrevida mediana global nos doentes que efetuaefetuaram ITK em 2.a e 3.a linha. Registo do material disponível para análise e demora média de resultado do exame, de acordo com o material enviado.ResultadosA sequenciação foi efetuada em 374 doentes, 71,1% sexo masculino, 67,1% não/ex-fumadores, 32,9% fumadores; 57,8% adenocarcinoma e 23,5% carcinoma epidermoide (CE). A mutação foi detetada em 49 doentes (13,1%). No total dos doentes estudados, a taxa de mutação foi de 9% no sexo masculino e 23% no sexo feminino. A sobrevida mediana global após o uso de erlotinib foi de 14 meses para os doentes com mutação positiva do EGFR versus 6 meses nos doentes não mutados (p = 0,003).ConclusãoO nosso grupo teve uma taxa de mutação global de 13,1%, com predomínio no sexo feminino, não fumadores, histologia adenocarcinoma. Em doentes selecionados (2006/2009), a taxa de mutação foi de 16%; nos doentes não selecionados (2010) foi de 10,4%. Este estudo tem vindo a permitir um melhor conhecimento da taxa de mutação do EGFR na população portuguesa, bem como avaliar os resultados das sobrevidas dos doentes após uso de inibidores da tirosina quinase (ITK), efetuada em 2.a e 3.a linha com conhecimento prévio do estado da mutação do EGFR, tendo sido encontradas diferenças nas sobrevidas nos 2 grupos de doentes (mutados e não mutados) com significado estatístico.A pesquisa mutação do EGFR deve ser efetuada em todos os doentes com CPNPC, dando possibilidade a um número considerável de doentes de poder efetuar um tratamento de 1.a linha com ITK (doentes mutados), bem como de poder usufruir de outros esquemas de quimioterapia, quando progredirem.AbstractIntroductionIn 2006, the Vila Nova de Gaia/Espinho Hospital Centre Pulmonary Oncology Unit started performing EGFR (Epidermal Growth Factor Receptor) mutation sequencing in selected patients with NSCLC and systematically in all patients since 2010, regardless of histology, smoking habits, age or sex. The aim of this study was to characterize the group of patients that carried out the sequencing between 2006-2010, to determine EGFR mutation frequency, to evaluate the overall survival and the survival after the use of tyrosine kinase inhibitors (TKI), in patients who performed this therapy in second and third line, knowing the EGFR mutation status.MethodsDescriptive statistical analysis of patients who did EGFR sequencing in 2006-2010 and of overall survival in patients treated with TKI as 2nd and 3rd line therapy. Record of the material available for analysis and average delay of exam results, according to the material submitted.ResultsThe sequencing was performed in 374 patients, 71,1% males, 67,1% non/ex-smokers, 32,9% smokers, 57,8% adenocarcinoma and 23,5% squamous cell carcinoma (SCC). The mutation was detected in 49 patients (13,1%). In all studied patients, the mutation rate was 9% in males and 23% in females. Median overall survival after erlotinib use of was 14 months for patients with positive EGFR mutation versus 6 months in not mutated patients (p = 0.003).ConclusionOur group had an overall mutation rate of 13.1% with female, non-smokers, adenocarcinoma histology predominance. In selected patients (2006/2009), the mutation rate was 16%, in not selected patients (2010) the mutation rate was 10.4%. This study has permitted a better understanding of the EGFR mutation rate in the Portuguese population as welll as an evaluation of the patients survival after the use of of tyrosine kinase inhibitors, in second and third line therapy with previous knowledge of the EGFR mutational status. Statistical significant differences in survival were found in the two patient groups (EGFR mutated and non mutated).The EGFR mutation research should be performed in all patients with NSCLC, giving the possibility to a considerable number of patients to perform a first line treatment with TKI (EGFR mutated patients) and the advantage of performing other chemotherapy schemes, when progression occurs

Exhortación a la instancia de la canonización del rey Jaime I de Aragón, llamado el Conquistador

Copia Digital. España : Ministerio de Cultura y Deporte. Subdirección General de Coordinación Bibliotecaria, 2022- L

Exhortación a la instancia de la canonización del rey Jaime I de Aragón, llamado el Conquistador

Enc. Rust.Sello de la Biblioteca Pública de la Ciudad de Zaragoza, Secciones Populares

Measurement of the J/Psi Production Cross Section in 920 GeV/c Fixed-Target Proton-Nucleus Interactions

The mid-rapidity (dsigma_(pN)/dy at y=0) and total sigma_(pN) production cross sections of J/Psi mesons are measured in proton-nucleus interactions. Data collected by the HERA-B experiment in interactions of 920 GeV/c protons with carbon, titanium and tungsten targets are used for this analysis. The J/Psi mesons are reconstructed by their decay into lepton pairs. The total production cross section obtained is sigma_(pN)(J/Psi) = 663 +- 74 +- 46 nb/nucleon. In addition, our result is compared with previous measurements

Search for the Flavor-Changing Neutral Current Decay D0→μ+μ−D^0 \to \mu^+\mu^- with the HERA-B Detector

We report on a search for the flavor-changing neutral current decay $D^0 \to \mu^+\mu^-$ using $50 \times 10^6$ events recorded with a dimuon trigger in interactions of 920 GeV protons with nuclei by the HERA-B experiment. We find no evidence for such decays and set a 90% confidence level upper limit on the branching fraction $Br(D^0 \to \mu^+\mu^-) <2.0 \times 10^{-6}$.Comment: 17 pages, 4 figures (of which 1 double), paper to be submitted to Physics Letters

Encapsulation of antioxidant phenolic compounds extracted from spent coffee grounds by freeze-drying and spray-drying using different coating materials

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.foodchem.2017.05.142.Freeze-drying and spray-drying techniques were evaluated for encapsulation of phenolic compounds (PC) extracted from spent coffee grounds. Additionally, the use of maltodextrin, gum arabic and a mixture of these components (ratio 1:1) as wall material to retain the PC and preserve their antioxidant activity was also assessed. The contents of PC and flavonoids (FLA), as well as the antioxidant activity of the encapsulated samples were determined in order to verify the efficiency of each studied condition. Additional analyses for characterization of the samples were also performed. Both the technique and the coating material greatly influenced the encapsulation of antioxidant PC. The best results were achieved when PC were encapsulated by freeze-drying using maltodextrin as wall material. Under these conditions, the amount of PC and FLA retained in the encapsulated sample corresponded to 62% and 73%, respectively, and 73-86% of the antioxidant activity present in the original extract was preserved.This work was supported by the Science and Technology Foundation of Portugal (FCT - grant SFRH/BD/80948/2011); the Strategic Project (PEst-OE/EQB/LA0023/2013); and the Project ‘‘BioInd - Biotechnology and Bioengineering for improved Industrial and Agro-Food processes” Co-funded by the Programa Operacional Regional do Norte (ON.2 – O Novo Norte), QREN, FEDER (Ref. NORTE-07-0124-FEDER-000028).info:eu-repo/semantics/publishedVersio

Inclusive V0V^0 Production Cross Sections from 920 GeV Fixed Target Proton-Nucleus Collisions

Inclusive differential cross sections $d\sigma_{pA}/dx_F$ and $d\sigma_{pA}/dp_t^2$ for the production of \kzeros, \lambdazero, and \antilambda particles are measured at HERA in proton-induced reactions on C, Al, Ti, and W targets. The incident beam energy is 920 GeV, corresponding to $\sqrt {s} = 41.6$ GeV in the proton-nucleon system. The ratios of differential cross sections \rklpa and \rllpa are measured to be $6.2\pm 0.5$ and $0.66\pm 0.07$, respectively, for \xf $\approx-0.06$. No significant dependence upon the target material is observed. Within errors, the slopes of the transverse momentum distributions $d\sigma_{pA}/dp_t^2$ also show no significant dependence upon the target material. The dependence of the extrapolated total cross sections $\sigma_{pA}$ on the atomic mass $A$ of the target material is discussed, and the deduced cross sections per nucleon $\sigma_{pN}$ are compared with results obtained at other energies.Comment: 17 pages, 7 figures, 5 table

Open and Hidden Charm Production in 920 GeV Proton-Nucleus Collisions

The HERA-B collaboration has studied the production of charmonium and open charm states in collisions of 920 GeV protons with wire targets of different materials. The acceptance of the HERA-B spectrometer covers negative values of xF up to xF=-0.3 and a broad range in transverse momentum from 0.0 to 4.8 GeV/c. The studies presented in this paper include J/psi differential distributions and the suppression of J/psi production in nuclear media. Furthermore, production cross sections and cross section ratios for open charm mesons are discussed.Comment: 5 pages, 9 figures, to be published in the proceedings of the 6th International Conference on Hyperons, Charm & Beauty Hadrons (BEACH04), Chicago, IL, June 27 - July 3, 200